I am an Associate Member in the Departments of Pharmacology and Therapeutics, Immunology and Medicine at Roswell Park Comprehensive Cancer Center (Roswell Park). I have extensive experience treating patients with myelodysplastic syndrome (MDS), acute leukemias (AL) and myeloproliferative disorders (MPN)s. As an attending physician on the leukemia service we treat more than 150 new patients with these diagnoses each year. I am a principal investigator on therapeutic studies in MDS and AL and the Associate Director for the Center for Early Phase Clinical Trials and the medical director for the Clinical Research Service. I have published several reports from phase 1 studies in patients with MDS based upon work translated directly from my laboratory. I have a particular interest in the immune milieu in MDS and other hematological cancers and have participated extensively in the CCC19 COVID and cancer registry effort.  My work focuses on translation of novel strategies for myeloid malignancy from the bench to the clinic. I am an active member of the RP graduate programs in Pharmacology and Therapeutics, Immunology and Medicine at the University of Buffalo, which have provided access to students for the lab. In collaboration with Dr. Michael Nemeth, a basic stem cell biologist and expert in mouse models, the lab has focused on immune function in malignant and normal hematopoiesis.